Therefore, a comprehensive understanding of the mechanism of PRAT-derived chemerin modulation of the lipid metabolism in cancer and tumor-associated macrophage activity may offer new perspectives for RCC therapy. The gene discussed is RARRES2; the disease is neoplasm.